Biomarin Pharmaceutical (BMRN) Amortization of Deferred Charges (2009 - 2026)

Biomarin Pharmaceutical has disclosed Amortization of Deferred Charges across 15 years of filings, most recently posting $6.1 million for Q1 2026.

• Quarterly Amortization of Deferred Charges rose 22440.74% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.8 million (up 653.1% YoY) and the FY2025 annual result came in at $2.6 million, down 21.94% from the prior year.
• Amortization of Deferred Charges advanced to $6.1 million in Q1 2026, from $653000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $6.1 million in Q1 2026 and troughed at $27000.0 in Q1 2025.
• A 5-year average of $785764.7 and a median of $149000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2025 — Amortization of Deferred Charges slumped 97.27% — and 2026, when it surged 22440.74%.
• Tracing BMRN's Amortization of Deferred Charges over 5 years: stood at $1.0 million in 2022, then fell by 3.7% to $990000.0 in 2023, then slumped by 33.33% to $660000.0 in 2024, then slipped by 1.06% to $653000.0 in 2025, then jumped by 832.01% to $6.1 million in 2026.
• Business Quant data shows BMRN's Amortization of Deferred Charges at $6.1 million in Q1 2026, $653000.0 in Q4 2025, and $27000.0 in Q3 2025.